Think10

www.Think-10.com is a life science business consultancy, a personal coaching and team development to all businesses and a service to the pharmaceutical industry to facilitate change,

Melanie Lee PhD, CBE, FMedSci, DSc(Hons)

LifeArc

Chief Executive Officer

Principal CEO

BTGplc

BTG plc is a fast growing exciting Interventional Medicine company - on the international stage with it's HQ in London. We have device and drug combination products in the Interventional vascular and oncology space and have recently entered the Interventional Pulmonary area with the acquisition of PneuMRx and their innovative coiled device to treat emphysema patients. Interventional medicine routes to the market place in the hands of skilled physicians is likely to be relevant to many of the emerging new modalities in the pipelines of our innovative biotechs today.

Chief Scientific Officer

NightstaRx Ltd

NightstaRx is a Syncona backed company established to pursue the gene therapy treatment of Choroideremia to prevent the deterioration of eyesight in patients with this X-linked disease which causes loss of sight during the mid 40-50 years of life. Early clinical studies by Robert MacLaren have shown promising efficacy and good safety. The therapy for this indication is to replace the faulty REP1 gene in the eye with a functioning copy in an AAV vector. NightstaRx aims to gain regulatory approval for this therapy with ensuring GMP of the product and agreeing the pivotal clinical path. Www.nightstarx.co.uk

NED (was Founding CEO during 2014)

Syntaxin Ltd

Syntaxin was a successful biotech spun out of the HPA that was developed by myself and my management team, with the help if course of our excellent scientists, to a stage for acquisition to ensure the further investment in the recombinant botulinum toxin technology. Ipsen acquired Syntaxin in July 2013 and the site continues as Ipsen's centre for toxin engineering, complementing well the Ipsen expertise in toxin biology. I left Syntaxin with the acquisition and now work through Think10 as I discuss new opportunities.

Chief Executive officer

EVP and President UCB NewMedicines

Breast Cancer Haven

Angel

Applied Genomics Link Scheme

Working to award funds to innovate collaborative programmes between strong academic groups and small companies.

Chairman

Celltech

EVP R&D, Celltech

Glaxo

Unit Head

I'm a passionate leader dedicated to driving innovation and positive impact in the life sciences industry.🔬

Throughout my career, I have championed the translation of scientific knowledge into impactful healthcare solutions and am passionate about fostering an environment that encourages multidisciplinary collaboration, nurtures scientific talent, and supports the next generation of innovators.

I actively engage with industry leaders, policymakers, and research institutions to shape the future of the life sciences ecosystem.

By participating in conferences, thought leadership activities, and industry forums, I strive to drive positive change and advance the boundaries of medical research.

I am always excited to speak with like-minded professionals, researchers, and individuals passionate about making a difference in healthcare. ⬇️

Let's amplify our impact in healthcare by connecting and collaborating towards a brighter future.🧑🏻‍🔬

Melanie Lee

Sound Bioventures

Managing Partner

Breye Therapeutics ApS

Brey Therapeutics is a clinical stage biotech compåany developing oral treatments for eye diseases like diabetic retinopathy

Board Director

SARomics Biostructures AB

SARomics Biostructures provides premium protein crystallization, protein crystallography and drug discovery services and develops their own in-house structure based drug discovery projects.

VHSQUARED LIMITED

VHsquared  developed orally available antibody domain drugs for IBD

Industrifonden

Industrifonden is one of the larger venture capital firms in the Nordics, backing growth companies in the Technology or Life Science sectors.

Senior Advisor

Lundbeckfonden / Lundbeck Foundation

Senior Advisor, Lundbeckfonden Ventures

Lundbeckfond Ventures was an evergreen life science venture fund wholly owned by the Lundbeck Foundation. The fund focused on Biotech and Pharma companies in Europe and USA,  It primarily invested in clinical projects in private companies in all therapeutic areas.

Senior Partner, Lundbeckfonden Ventures

Enterome

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.

Board Director, Compensation Committee Chair

Athera Biotechnologies AB

Athera Biotechnologies AB was a clinical stage company studying vascular inflammation with an anti-inflammatory antibody

Reneo Pharmaceuticals

Reneo Pharmaceuticals is listed on NASDAQ and is developing a clinical stage small molecule to treat severe orphan genetic diseases that presently have no pharmaceutical treatments

Amplyx Pharmaceuticals, Inc

Amplyx Pharmaceuticals was developing novel, broad-spectrum anti-fungal agents for the treatment of life-threatening fungal and mold infections. It was acquired by Pfizer in April 2021.

Venture Investing, company creation and board work across Europe and USA. 
Long operational experience from the Pharma and Biotech Industry as a CEO, in Business Development and in R&D  project and people management.

taplio

The Battle

Melanie Lee

Johan Kördel

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?